- Home
- JXG vs APM Comparison
JXG vs APM Comparison
Compare JXG & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JXG | APM |
|---|---|---|
| Founded | N/A | 2010 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 10.7M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | JXG | APM |
|---|---|---|
| Price | $7.91 | $1.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 203.8K | 50.5K |
| Earning Date | 05-14-2026 | 12-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.26 | N/A |
| Revenue | ★ $46,835,624.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.54 | ★ N/A |
| Revenue Growth | ★ 21.68 | N/A |
| 52 Week Low | $3.01 | $0.69 |
| 52 Week High | $73.80 | $7.49 |
Technical Indicators
Market Signals| Indicator | JXG | APM |
|---|---|---|
| Relative Strength Index (RSI) | 60.94 | 37.49 |
| Support Level | $8.44 | $1.08 |
| Resistance Level | $10.00 | $1.23 |
| Average True Range (ATR) | 1.62 | 0.09 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 51.03 | 15.63 |
Price Performance
Historical ComparisonAbout JXG JX Luxventure Limited
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.